Immunic, Inc. Common Stock (IMUX) is a publicly traded Healthcare sector company. As of September 1, 2026, IMUX trades at $16.05 with a market cap of $210.12M and a P/E ratio of -25.57. IMUX moved +1.60% today. Year to date, IMUX is +196.05%; over the trailing twelve months it is +92.68%. Its 52-week range spans $5.06 to $17.43. Analyst consensus is strong buy with an average price target of $43.60. Rallies surfaces IMUX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks IMUX insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $16.05 |
| Market Cap | $210.12M |
| P/E Ratio | -25.57 |
| EPS | $-0.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.43 |
| 52-Week Low | $5.06 |
| Volume | 966 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-97.17M |
| Gross Margin | 0.00% |
6 analysts cover IMUX: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $43.60.